Bionano Genomics Q4 revenue falls as instrument sales decline

Reuters03-24

<a href="https://laohu8.com/S/BNGO">Bionano Genomics</a> Q4 revenue falls as instrument sales decline

Overview

Genome analysis provider's Q4 revenue fell 3% yr/yr as instrument sales declined
Company improved Q4 gross margin to 43% from 42% yr/yr
Operating expenses for Q4 fell 22% yr/yr

Outlook

Company sees Q1 2026 revenue between $6.5 mln and $6.7 mln
Bionano expects 2026 revenue of $30 mln to $33 mln

Result Drivers

INSTRUMENT SALES - Q4 instrument revenue decreased slightly from prior year, contributing to overall revenue decline
FLOWCELL SALES - Sold 7,554 nanochannel array flowcells in Q4 2025, down 6% from Q4 2024, impacting consumables revenue

Company press release: ID:nGNX1gWsb3

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue		$8 mln
Q4 Gross Margin		43%
Q4 Adjusted Operating Expenses		$9.7 mln
Q4 Operating Expenses		$11.9 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Bionano Genomics Inc is $5.50, about 378.3% above its March 20 closing price of $1.15

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621843900?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 04:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621843900","market":"nz","top_or_hot":-1,"title":"Bionano Genomics Q4 revenue falls as instrument sales decline","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a> Q4 revenue falls as instrument sales decline</title></head><body><p><span>Overview</span></p><ul><li><p>Genome analysis provider's Q4 revenue fell 3% yr/yr as instrument sales declined</p></li><li><p>Company improved Q4 gross margin to 43% from 42% yr/yr</p></li><li><p>Operating expenses for Q4 fell 22% yr/yr</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company sees Q1 2026 revenue between $6.5 mln and $6.7 mln</p></li><li><p>Bionano expects 2026 revenue of $30 mln to $33 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INSTRUMENT SALES - Q4 instrument revenue decreased slightly from prior year, contributing to overall revenue decline</p></li><li><p>FLOWCELL SALES - Sold 7,554 nanochannel array flowcells in Q4 2025, down 6% from Q4 2024, impacting consumables revenue</p></li></ul><p>Company press release: <span>ID:nGNX1gWsb3</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td></td><td><p>$8 mln</p></td><td></td></tr><tr><td><p>Q4 Gross Margin</p></td><td></td><td><p>43%</p></td><td></td></tr><tr><td><p>Q4 Adjusted Operating Expenses</p></td><td></td><td><p>$9.7 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$11.9 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Bionano Genomics Inc is $5.50, about 378.3% above its March 20 closing price of $1.15</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bionano Genomics Q4 revenue falls as instrument sales decline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBionano Genomics Q4 revenue falls as instrument sales decline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-24 04:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a> Q4 revenue falls as instrument sales decline</title></head><body><p><span>Overview</span></p><ul><li><p>Genome analysis provider's Q4 revenue fell 3% yr/yr as instrument sales declined</p></li><li><p>Company improved Q4 gross margin to 43% from 42% yr/yr</p></li><li><p>Operating expenses for Q4 fell 22% yr/yr</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company sees Q1 2026 revenue between $6.5 mln and $6.7 mln</p></li><li><p>Bionano expects 2026 revenue of $30 mln to $33 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INSTRUMENT SALES - Q4 instrument revenue decreased slightly from prior year, contributing to overall revenue decline</p></li><li><p>FLOWCELL SALES - Sold 7,554 nanochannel array flowcells in Q4 2025, down 6% from Q4 2024, impacting consumables revenue</p></li></ul><p>Company press release: <span>ID:nGNX1gWsb3</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td></td><td><p>$8 mln</p></td><td></td></tr><tr><td><p>Q4 Gross Margin</p></td><td></td><td><p>43%</p></td><td></td></tr><tr><td><p>Q4 Adjusted Operating Expenses</p></td><td></td><td><p>$9.7 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$11.9 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Bionano Genomics Inc is $5.50, about 378.3% above its March 20 closing price of $1.15</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0154245673.USD","symbol_name":"BNP PARIBAS US MID CAP \"C\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nL1N40B13M:1","article_id":"2621843900","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621843900","pubTimestamp":1774297189,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Bionano Genomics Q4 revenue falls as instrument sales declineOverviewGenome analysis provider's Q4 revenue fell 3% yr/yr as instrument sales declinedCompany improved Q4 gross margin to 43% from 42% yr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","BK4121":"生命科学工具和服务","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","BK4575":"芯片概念","BK4567":"ESG概念","BNGO":"Bionano Genomics","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","CMI":"康明斯","BK4149":"建筑机械与重型卡车","BK4585":"ETF&股票定投概念","BK4588":"碎股"},"translate_title":"由于仪器销售下降，Bionano Genomics第四季度收入下降","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMI":0.9,"BNGO":0.9},"content_text":"Bionano Genomics Q4 revenue falls as instrument sales declineOverviewGenome analysis provider's Q4 revenue fell 3% yr/yr as instrument sales declinedCompany improved Q4 gross margin to 43% from 42% yr/yrOperating expenses for Q4 fell 22% yr/yrOutlookCompany sees Q1 2026 revenue between $6.5 mln and $6.7 mlnBionano expects 2026 revenue of $30 mln to $33 mlnResult DriversINSTRUMENT SALES - Q4 instrument revenue decreased slightly from prior year, contributing to overall revenue declineFLOWCELL SALES - Sold 7,554 nanochannel array flowcells in Q4 2025, down 6% from Q4 2024, impacting consumables revenueCompany press release: ID:nGNX1gWsb3Key DetailsMetricBeat/MissActualConsensus EstimateQ4 Revenue$8 mlnQ4 Gross Margin43%Q4 Adjusted Operating Expenses$9.7 mlnQ4 Operating Expenses$11.9 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the advanced medical equipment & technology peer group is \"buy\"Wall Street's median 12-month price target for Bionano Genomics Inc is $5.50, about 378.3% above its March 20 closing price of $1.15For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621843900","isCrawlerRequest":true}